These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28094040)

  • 41. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.
    Look KY; Sandler A; Blessing JA; Lucci JA; Rose PG;
    Gynecol Oncol; 2004 Feb; 92(2):644-7. PubMed ID: 14766260
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.
    Makker V; Filiaci VL; Chen LM; Darus CJ; Kendrick JE; Sutton G; Moxley K; Aghajanian C
    Gynecol Oncol; 2015 Jul; 138(1):24-9. PubMed ID: 25888978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II study of paclitaxel in combination with carboplatin for patients with recurrent or persistent uterine sarcoma.
    Yoo HJ; Lim MC; Lim S; Park JY; Kang S; Park SY; Seo SS
    Arch Gynecol Obstet; 2012 Dec; 286(6):1529-35. PubMed ID: 22825691
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Modesitt SC; Sill M; Hoffman JS; Bender DP;
    Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.
    Campos SM; Brady WE; Moxley KM; O'Cearbhaill RE; Lee PS; DiSilvestro PA; Rotmensch J; Rose PG; Thaker PH; O'Malley DM; Hanjani P; Zuna RE; Hensley ML
    Gynecol Oncol; 2014 Jun; 133(3):537-41. PubMed ID: 24594074
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group.
    Muss HB; Bundy BN; Adcock L; Beecham J
    Am J Clin Oncol; 1990 Feb; 13(1):32-4. PubMed ID: 2154921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
    George S; Feng Y; Manola J; Nucci MR; Butrynski JE; Morgan JA; Ramaiya N; Quek R; Penson RT; Wagner AJ; Harmon D; Demetri GD; Krasner C
    Cancer; 2014 Mar; 120(5):738-43. PubMed ID: 24222211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
    Rose PG; Blessing JA; Soper JT; Barter JF
    Gynecol Oncol; 1998 Aug; 70(2):267-71. PubMed ID: 9740703
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib.
    Nagamata S; Ebina Y; Yamano Y; Miyamoto T; Nishijima M; Yamada H
    Kobe J Med Sci; 2016 Jul; 62(2):E45-8. PubMed ID: 27578036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
    Ingham M; Allred JB; Chen L; Das B; Kochupurakkal B; Gano K; George S; Attia S; Burgess MA; Seetharam M; Boikos SA; Bui N; Chen JL; Close JL; Cote GM; Thaker PH; Ivy SP; Bose S; D'Andrea A; Marino-Enriquez A; Shapiro GI; Schwartz GK
    J Clin Oncol; 2023 Sep; 41(25):4154-4163. PubMed ID: 37467452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
    Coleman RL; Sill MW; Thaker PH; Bender DP; Street D; McGuire WP; Johnston CM; Rotmensch J
    Gynecol Oncol; 2015 Jul; 138(1):30-5. PubMed ID: 25887099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
    Falchook GS; Zhou X; Venkatakrishnan K; Kurzrock R; Mahalingam D; Goldman JW; Jung J; Ullmann CD; Milch C; Rosen LS; Sarantopoulos J
    Drugs R D; 2016 Mar; 16(1):45-52. PubMed ID: 26689566
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of alisertib in treatment of peripheral T-cell lymphomas.
    Gallop-Evans E
    Future Oncol; 2015 Sep; 11(18):2515-24. PubMed ID: 26344156
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib.
    Necchi A; Pintarelli G; Raggi D; Giannatempo P; Colombo F
    Invest New Drugs; 2017 Aug; 35(4):524-528. PubMed ID: 28155045
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improved clinical trial enrollments for uterine leiomyosarcoma patients after gynecologic oncology partnership with a sarcoma center.
    Lange SE; Liu J; Adkins DR; Powell MA; Van Tine BA; Mutch DG
    Gynecol Oncol; 2016 Feb; 140(2):307-12. PubMed ID: 26718726
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
    Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
    Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
    Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
    Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aminothiadiazole in the treatment of advanced leiomyosarcoma of the uterine corpus. A Gynecologic Oncology Group study.
    Asbury R; Blessing JA; Smith DM; Carson LF
    Am J Clin Oncol; 1995 Oct; 18(5):397-9. PubMed ID: 7572755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
    Powell MA; Sill MW; Goodfellow PJ; Benbrook DM; Lankes HA; Leslie KK; Jeske Y; Mannel RS; Spillman MA; Lee PS; Hoffman JS; McMeekin DS; Pollock PM
    Gynecol Oncol; 2014 Oct; 135(1):38-43. PubMed ID: 25019571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
    Chan JK; Brady W; Monk BJ; Brown J; Shahin MS; Rose PG; Kim JH; Secord AA; Walker JL; Gershenson DM
    Gynecol Oncol; 2018 Aug; 150(2):247-252. PubMed ID: 29921512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.